Hansa Biopharma AB (publ) (HNSA.ST)
SEK 33.3
(17.42%)
SEK 33.3
(17.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -788.49 Million SEK | -37.28% |
| 2022 | -576.12 Million SEK | -6.77% |
| 2021 | -539.58 Million SEK | -26.94% |
| 2020 | -425.07 Million SEK | -18.87% |
| 2019 | -357.59 Million SEK | -45.07% |
| 2018 | -246.49 Million SEK | -39.99% |
| 2017 | -176.08 Million SEK | -58.44% |
| 2016 | -111.13 Million SEK | -67.88% |
| 2015 | -66.2 Million SEK | -167.92% |
| 2014 | -24.7 Million SEK | -40.08% |
| 2013 | -17.63 Million SEK | -4.95% |
| 2012 | -16.8 Million SEK | -168.7% |
| 2011 | 24.46 Million SEK | 222.37% |
| 2010 | -19.99 Million SEK | -27.01% |
| 2009 | -15.74 Million SEK | 1.04% |
| 2008 | -15.9 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -181.67 Million SEK | -18.83% |
| 2024 Q3 | -116.92 Million SEK | 35.64% |
| 2024 Q1 | -152.89 Million SEK | 15.97% |
| 2023 Q1 | -182.34 Million SEK | -24.69% |
| 2023 Q3 | -202.15 Million SEK | 11.51% |
| 2023 FY | -790.87 Million SEK | -37.28% |
| 2023 Q4 | -181.95 Million SEK | 9.99% |
| 2023 Q2 | -228.45 Million SEK | -25.28% |
| 2022 Q2 | -167.83 Million SEK | -18.41% |
| 2022 Q1 | -141.73 Million SEK | 12.91% |
| 2022 FY | -576.12 Million SEK | -6.77% |
| 2022 Q4 | -146.24 Million SEK | -4.84% |
| 2022 Q3 | -139.49 Million SEK | 16.89% |
| 2021 Q2 | -132.35 Million SEK | -27.65% |
| 2021 Q1 | -103.68 Million SEK | 2.35% |
| 2021 FY | -539.58 Million SEK | -26.94% |
| 2021 Q3 | -148.17 Million SEK | -11.95% |
| 2021 Q4 | -162.75 Million SEK | -9.84% |
| 2020 FY | -425.07 Million SEK | -18.87% |
| 2020 Q1 | -91.35 Million SEK | 17.04% |
| 2020 Q2 | -101.82 Million SEK | -11.47% |
| 2020 Q3 | -123.44 Million SEK | -21.23% |
| 2020 Q4 | -106.18 Million SEK | 13.98% |
| 2019 Q4 | -110.11 Million SEK | -18.16% |
| 2019 Q3 | -93.19 Million SEK | -11.36% |
| 2019 Q2 | -83.68 Million SEK | -15.14% |
| 2019 Q1 | -72.68 Million SEK | 9.83% |
| 2019 FY | -357.59 Million SEK | -45.07% |
| 2018 FY | -246.49 Million SEK | -39.99% |
| 2018 Q1 | -46.62 Million SEK | 4.7% |
| 2018 Q4 | -80.6 Million SEK | -33.22% |
| 2018 Q3 | -60.5 Million SEK | -2.95% |
| 2018 Q2 | -58.76 Million SEK | -26.05% |
| 2017 Q3 | -37.43 Million SEK | 16.63% |
| 2017 Q4 | -48.92 Million SEK | -30.69% |
| 2017 FY | -176.08 Million SEK | -58.44% |
| 2017 Q1 | -44.82 Million SEK | -33.56% |
| 2017 Q2 | -44.9 Million SEK | -0.17% |
| 2016 Q1 | -19.94 Million SEK | -4.49% |
| 2016 FY | -111.13 Million SEK | -67.88% |
| 2016 Q3 | -26.95 Million SEK | 12.13% |
| 2016 Q4 | -33.56 Million SEK | -24.52% |
| 2016 Q2 | -30.67 Million SEK | -53.79% |
| 2015 FY | -66.2 Million SEK | -167.92% |
| 2015 Q1 | -10.68 Million SEK | -24.9% |
| 2015 Q3 | -13.92 Million SEK | 38.09% |
| 2015 Q2 | -22.49 Million SEK | -110.46% |
| 2015 Q4 | -19.08 Million SEK | -37.06% |
| 2014 Q3 | -5.42 Million SEK | -12.14% |
| 2014 Q4 | -8.55 Million SEK | -57.87% |
| 2014 Q1 | -5.89 Million SEK | -31.17% |
| 2014 Q2 | -4.83 Million SEK | 18.01% |
| 2014 FY | -24.7 Million SEK | -40.08% |
| 2013 Q3 | -4.49 Million SEK | -4.05% |
| 2013 Q2 | -4.31 Million SEK | 0.0% |
| 2013 Q4 | -4.49 Million SEK | 0.0% |
| 2013 Q1 | -4.31 Million SEK | -22.42% |
| 2013 FY | -17.63 Million SEK | -4.95% |
| 2012 Q4 | -3.52 Million SEK | 0.0% |
| 2012 FY | -16.8 Million SEK | -168.7% |
| 2011 FY | 24.46 Million SEK | 222.37% |
| 2010 FY | -19.99 Million SEK | -27.01% |
| 2009 FY | -15.74 Million SEK | 1.04% |
| 2008 FY | -15.9 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | -216.687% |
| Ziccum AB (publ) | -21.56 Million SEK | -3557.217% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -4707.609% |
| BioArctic AB (publ) | 252.64 Million SEK | 412.103% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -93213.136% |
| Mendus AB (publ) | -100.65 Million SEK | -683.404% |
| Genovis AB (publ.) | 54.22 Million SEK | 1554.146% |
| Intervacc AB (publ) | -93.57 Million SEK | -742.599% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -4983.136% |
| Active Biotech AB (publ) | -46.48 Million SEK | -1596.274% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 4478.344% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -1322.841% |
| Aptahem AB (publ) | -10.1 Million SEK | -7703.214% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | -145.251% |
| Kancera AB (publ) | -65.04 Million SEK | -1112.287% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -485.733% |
| Fluicell AB (publ) | -26.87 Million SEK | -2833.502% |
| Saniona AB (publ) | -81.06 Million SEK | -872.671% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -6273.745% |
| Biovica International AB (publ) | -126.07 Million SEK | -525.428% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -1755.066% |
| AcouSort AB (publ) | -17.48 Million SEK | -4409.041% |
| Xintela AB (publ) | -57.23 Million SEK | -1277.574% |
| Abliva AB (publ) | -96.54 Million SEK | -716.688% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | -142.764% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -22396.32% |
| OncoZenge AB (publ) | -15.9 Million SEK | -4858.471% |
| Amniotics AB (publ) | -29.07 Million SEK | -2612.125% |
| 2cureX AB (publ) | -36.36 Million SEK | -2068.402% |
| CombiGene AB (publ) | -36.3 Million SEK | -2071.857% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -5285.902% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | -105.125% |
| Camurus AB (publ) | 532.35 Million SEK | 248.115% |
| Corline Biomedical AB | -1.78 Million SEK | -43999.329% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -336.199% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -1791.649% |
| I-Tech AB | 24.43 Million SEK | 3326.912% |
| Cyxone AB (publ) | -21.66 Million SEK | -3540.164% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -644.11% |
| Biosergen AB | -27.26 Million SEK | -2791.971% |
| Cantargia AB (publ) | -290.01 Million SEK | -171.879% |
| NextCell Pharma AB | -43.17 Million SEK | -1726.401% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -336.199% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -4512.092% |
| Nanologica AB (publ) | -69.96 Million SEK | -1027.019% |
| SynAct Pharma AB | -224.49 Million SEK | -251.229% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -1684.897% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -3191.672% |
| LIDDS AB (publ) | -40.67 Million SEK | -1838.575% |
| Lipum AB (publ) | -37.25 Million SEK | -2016.541% |
| BioInvent International AB (publ) | -369.94 Million SEK | -113.14% |
| Alzinova AB (publ) | -16.52 Million SEK | -4672.401% |
| Oncopeptides AB (publ) | -253.44 Million SEK | -211.109% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -12233.26% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -585.214% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -3815.269% |
| Simris Alg AB (publ) | -36.63 Million SEK | -2052.302% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -437.976% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | -154.004% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -610.908% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -6717.361% |